Attenuated tuberculosis vaccine study in HIV co-infected individuals
Official title: Evaluating the safety, immunogenicity and efficacy of a robust attenuated Mtb vaccine in the setting of HIV co-infection
Funded at Texas Biomedical Research Institute · NIH-11357706 · Data updated 2026-11-12
A new, weakened tuberculosis vaccine approach is being tested to see if it can safely and effectively protect people who also have HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Biomedical Research Institute NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | June 17, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $893,004 |
| NIH project number | 5R01AI189313-02 |
| Project ID | NIH-11357706 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for TB who may also be living with HIV and could be considered for future vaccine trials.
✕Less likely to help
Patients without HIV or those not at risk for TB may not directly benefit from this vaccine strategy in its early stages.
What this research studies
This project tests an attenuated Mycobacterium tuberculosis vaccine in the context of HIV infection to see how safe and how immune-boosting it is, with a focus on how the body’s immune cells respond in the lungs. Researchers will evaluate immune signals, T and B cell cooperation, and the presence of immune structures in lung tissue using non-human primate models as a stepping stone before human studies. The ultimate goal is durable protection against TB by generating strong, lasting immune responses that work well even when HIV is present. The study builds on prior work showing protection in macaques and aims to translate those findings toward safe human use.
Why it matters
Potential benefit: If successful, this vaccine approach could offer longer-lasting protection against TB, potentially reducing TB deaths and transmission in people at risk, including those with HIV.
How similar studies have gone: Previous animal studies showed strong protection and helpful immune responses, supporting progression to more translational work.
Where this research is happening
-
Texas Biomedical Research Institute
San Antonio, United States Active
Researchers
- Principal investigator: Kaushal, Deepak — Texas Biomedical Research Institute
- Study coordinator: Kaushal, Deepak
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.